July 15, 2008

David J. Mulvaney, M.D. Joins Ultroid(R) Technologies Inc. And Vascular Technologies Inc. As New Medical Affairs Director

Ultroid(R) Technologies Inc. and Vascular Technologies, Inc., announce today that David J. Mulvaney, M.D. has joined the Company as Medical Affairs Director. Dr. Mulvaney will be responsible for overseeing medical research, data acquisition, and the medical publication process, in addition to facilitating training and education of our doctor network and key distributor partners.

Dr. Mulvaney is a graduate of the University Of Alabama School Of Medicine in Birmingham, Alabama. He trained in general surgery in Macon, Georgia and thoracic surgery in Miami, Florida. He was board certified in general surgery in 1997 and in thoracic surgery in 2000. He has practiced general and thoracic surgery as well as emergency medicine in Florida since 2003. Dr. Mulvaney was involved in immunobiology research at the U.A. B. School of Medicine and Institute Pasteur in Paris, France for a total of 4 years. He published a sentinel article on B cell development in Nature in 1986 after his work in Paris.

"Ultroid(R) and Vascular Technologies are very pleased to bring Dr. Mulvaney on board. He will facilitate delivering on our promise to bring superior patient care and to help family practitioners and other doctors understand `how to' and `how easy it is to' administer the Ultroid(R) procedure," commented Brent Willis, CEO, who recently joined following stints at Cott Corporation (COT), InBev (INB.BR), and the Coca-Cola Company (KO). "With Dr. Mulvaney's extensive medical experience we will be able to accelerate the learning curve of both physicians and patients with broader scale communication on Ultroid(R) becoming the "standard of care" for the painless treatment of hemorrhoids and potentially other varicose veins.

About Vascular Technologies and Ultroid Technologies

Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the breakthrough Ultroid(R) Medical System, a less expensive and more effective treatment than current procedures for the treatment of hemorrhoids with new applications for other varicose and spider veins. Ultroid(R) is a painless, non-invasive outpatient treatment with an over 90% effective rate that replaces ineffective over-the-counter creams and painful surgeries that can be accompanied by infection and prolonged recovery. The Ultroid(R) procedure can be performed by any physician, regardless of specialty, in their office, in approximately 10-15 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid(R) is FDA-cleared and accepted by most insurers and Medicare.

The Company's website is www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid(R) Technologies, Inc., its affiliated companies, customers, or other third parties. The Company manages web video-enabled training clinics and markets and manufactures the Ultroid(R) Medical Devices.

Safe Harbor Statements

This press release may contain forward-looking statements reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.